



Rx Only

cobas[®] SARS-CoV-2 & Influenza A/B

Nucleic acid test for use on the cobas[®] Liat[®] System

For in vitro diagnostic use

cobas[®] SARS-CoV-2 & Influenza A/B

P/N: 09211101190

cobas[®] SARS-CoV-2 & Influenza A/B Quality Control Kit

P/N: 09211128190

Table of contents

Intended use	4
Summary and explanation of the test.....	4
Reagents and materials	6
cobas® SARS-CoV-2 & Influenza A/B reagents and controls	6
Reagent storage and handling.....	9
Additional materials required	10
Instrumentation and software required	10
Precautions and handling requirements	10
Warnings and precautions	10
Sample collection, transport, and storage.....	12
Sample collection.....	12
Transport and storage.....	12
Instructions for use	13
Procedural notes	13
Running cobas® SARS-CoV-2 & Influenza A/B.....	13
Test procedure	14
cobas® SARS-CoV-2 & Influenza A/B assay tube Lot Validation.....	15
Materials needed for Lot Validation	15
Prepare and test Negative Control sample	15
Assay tube Lot Validation workflow.....	16
Prepare cobas® SARS-CoV-2 & Influenza A/B Positive Control sample and continue with Lot Validation	18
Performing additional control runs.....	21
Results	22
Quality control and interpretation of results.....	22
Procedural limitations	25

Non-clinical performance – SARS-CoV-2.....	26
Key performance characteristics.....	26
Analytical sensitivity.....	26
Reactivity/inclusivity.....	27
Cross reactivity- <i>In Silico</i> Analysis	27
Cross reactivity - Wet Laboratory Testing.....	28
Cross reactivity with SARS-CoV-1	28
Cross reactivity/Microbial Interference with other microorganisms.....	29
Co-infection (competitive inhibition).....	30
Clinical performance evaluation – SARS-CoV-2	32
Non-clinical performance - Influenza A/B.....	35
Analytical sensitivity	35
Reproducibility	35
Reactivity/inclusivity.....	37
Cross reactivity	39
Interfering microorganisms.....	40
Interfering substances.....	41
Clinical studies - Influenza A/B.....	42
Failure codes.....	44
Additional information.....	45
Key test features.....	45
Symbols	46
Technical support.....	48
Manufacturer and distributors.....	48
Trademarks and patents.....	48
Copyright	48
References	49
Document revision.....	51

Intended use

The **cobas**® SARS-CoV-2 & Influenza A/B Nucleic acid test for use on the **cobas**® Liat® System (**cobas**® SARS-CoV-2 & Influenza A/B) is an automated multiplex real-time RT-PCR assay intended for the simultaneous rapid *in vitro* qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B virus RNA in healthcare provider-collected nasopharyngeal and nasal swabs and self-collected nasal swabs (collected in a healthcare setting with instruction by a healthcare provider) from individuals suspected of a viral respiratory infection.

cobas® SARS-CoV-2 & Influenza A/B is intended for use in the simultaneous rapid *in vitro* detection and differentiation of SARS-CoV-2, influenza A virus, and influenza B virus nucleic acid in clinical specimens and is not intended to detect influenza C virus. SARS-CoV-2, influenza A and influenza B viral RNA is generally detectable in respiratory specimens during the acute phase of infection. Positive results are indicative of active infection but do not rule out bacterial infection or co-infection with other pathogens not detected by the test. Clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. The agent detected may not be the definite cause of disease.

Negative results do not preclude infection from SARS-CoV-2, influenza A, and/or influenza B and should not be used as the sole basis for diagnosis, treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and/or epidemiological information.

cobas® SARS-CoV-2 & Influenza A/B is intended for use by health professionals or trained operators who are proficient in using the **cobas**® Liat® System at the point of care (POC) or in a clinical laboratory setting.

Summary and explanation of the test

Background

Coronavirus disease 2019 (COVID-19) is a respiratory illness caused by a novel human coronavirus, named SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) by the World Health Organization.¹⁻³ COVID-19 has been declared a public health emergency of international concern and is the first pandemic caused by coronavirus.^{4,5} Amidst global concerns over COVID-19, influenza A and B viruses continue to circulate and also cause acute respiratory disease. COVID-19 and influenza are potentially fatal infections that result in significant worldwide morbidity and mortality.⁶

Rapid and accurate diagnosis and differentiation of SARS-CoV-2 and influenza infections is important in individuals suspected of a respiratory infection. The seasonality of COVID-19 and influenza overlap and the clinical manifestations of the two diseases can be similar, ranging from asymptomatic or mild “influenza-like” illness (such as fever, cough, shortness of breath, or myalgia) in a majority of individuals to more severe and life-threatening disease.⁷⁻⁹ The current widespread implementation of rapid point of care (POC) testing for influenza underscores the importance of prompt and accurate detection.¹⁰ Rapid and accurate detection of both SARS-CoV-2 and influenza can help to inform time-critical medical decision-making, facilitate infection control efforts, promote efficient resourcing, optimize use of targeted therapies and antimicrobials, and reduce ancillary testing or procedures.^{11,12}

Explanation of the test

cobas® SARS-CoV-2 & Influenza A/B uses real-time reverse transcriptase polymerase chain reaction (RT-PCR) technology to rapidly (approximately 20 minutes) detect and differentiate between SARS-CoV-2, influenza A, and influenza B viruses from

nasopharyngeal and nasal swabs. The automation, small footprint, and easy-to-use interface of the **cobas® Liat®** System enable performance of this test to occur at the POC or in a clinical laboratory setting.

Principles of the procedure

cobas® SARS-CoV-2 & Influenza A/B is performed on the **cobas® Liat®** Analyzer which automates and integrates sample purification, nucleic acid amplification, and detection of the target sequence in biological samples using real-time RT-PCR assays. The assay targets both the ORF1 a/b non-structural region and nucleocapsid protein gene that are unique to SARS-CoV-2, a well-conserved region of the matrix gene of influenza A, and the non-structural protein gene of influenza B. An Internal Process Control (IPC) is also included. The IPC is present to control for adequate processing of the target virus through steps of sample purification, nucleic acid amplification, and to monitor the presence of inhibitors in the RT-PCR processes.

Reagents and materials

The materials provided for cobas® SARS-CoV-2 & Influenza A/B can be found in Table 1 and Table 2. Reagent handling and storage can be found in Table 3. Materials required, but not provided can be found in Table 4 and Table 5.

Refer to the **Reagents and materials** section and **Precautions and handling requirements** section for the hazard information for the product.

cobas® SARS-CoV-2 & Influenza A/B reagents and controls

All unopened assay tubes and controls shall be stored as recommended in Table 1 to Table 3.

Table 1: cobas® SARS-CoV-2 & Influenza A/B

cobas® SARS-CoV-2 & Influenza A/B		
Store at 2-8°C 20 tests (P/N 09211101190) 20 transfer pipettes 1 Package Insert Barcode Card		
Reagents in cobas® SARS-CoV-2 & Influenza A/B assay tube	Reagent ingredients	Safety symbol and warning ^a
cobas® Liat® Internal Process Control	Tris buffer, tween-80, polyethylene glycol, EDTA, < 0.001% stock bacteriophage MS2 (inactivated), 0.002% carrier RNA, 0.01% ProClin® 300 preservative ^b	EUH210 Safety data sheet available on request. EUH208 Contains reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1). May produce an allergic reaction.
Proteinase K	100% Proteinase K	N/A
cobas® Liat® Magnetic Glass Particles	Magnetic Glass Particles	N/A


cobas® SARS-CoV-2 & Influenza A/B

Store at 2-8°C

20 tests (P/N 09211101190)

20 transfer pipettes

1 Package Insert Barcode Card


Reagents in cobas® SARS-CoV-2 & Influenza A/B assay tube	Reagent ingredients	Safety symbol and warning ^a
cobas® Liat® Lysis Buffer	Citric acid, sodium phosphate, 42.6% guanidinium isothiocyanate ^b , 5% decaethylene glycol monododecyl ether ^b , dithiothreitol	 <p>DANGER</p> <p>H302 + H332 Harmful if swallowed or if inhaled.</p> <p>H314 Causes severe skin burns and eye damage.</p> <p>H412 Harmful to aquatic life with long lasting effects.</p> <p>EUH032 Contact with acids liberates very toxic gas.</p> <p>P261 Avoid breathing dust/fume/gas/mist/vapours/spray.</p> <p>P273 Avoid release to the environment.</p> <p>P280 Wear protective gloves/protective clothing/eye protection/face protection.</p> <p>P303 + P361 + P353 IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water.</p> <p>P304 + P340 + P310 IF INHALED Remove person to fresh air and keep comfortable for breathing. Immediately call a POISON CENTER/doctor.</p> <p>P305 + P351 + P338 + P310 IF IN EYES Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.</p> <p>593-84-0 Guanidinium thiocyanate</p> <p>9002-92-0 Brij 35</p>
cobas® Liat® Wash Buffer	Glycine, potassium fluoride, 0.01% ProClin® 300 preservative	N/A
cobas® Liat® Elution Buffer	Trehalose, tris buffer, magnesium sulfate, bovine serum albumin, 0.01% ProClin® 300 preservative ^b	<p>EUH210 Safety data sheet available on request.</p> <p>EUH208 Contains reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1). May produce an allergic reaction.</p>

cobas® SARS-CoV-2 & Influenza A/B Store at 2-8°C 20 tests (P/N 09211101190) 20 transfer pipettes 1 Package Insert Barcode Card		
Reagents in cobas® SARS-CoV-2 & Influenza A/B assay tube	Reagent ingredients	Safety symbol and warning ^a
cobas® Liat® SARS-CoV-2 & Influenza A/B Master Mix-1	Tween-80, tris buffer, trehalose, potassium chloride, bovine serum albumin, dATP, dCTP, dGTP, dUTP, 0.01% ProClin® 300 preservative ^b , < 0.001% downstream <i>SARS-CoV-2</i> , <i>Influenza A</i> , <i>Influenza B</i> and Internal Process Control primers	EUH210 Safety data sheet available on request. EUH208 Contains reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1). May produce an allergic reaction.
cobas® Liat® SARS-CoV-2 & Influenza A/B Master Mix-2	Tween-80, tween-20, tris buffer, glycerol, potassium chloride, EDTA, dithiothreitol, < 0.01% Z05 polymerase with aptamer, 0.23% MMLV Reverse Transcriptase	N/A
cobas® Liat® SARS-CoV-2 & Influenza A/B Master Mix-3	Tween-80, tris buffer, EDTA, trehalose, potassium chloride, bovine serum albumin, < 0.001% upstream <i>SARS-CoV-2</i> , <i>Influenza A</i> , <i>Influenza B</i> and Internal Control primers, < 0.01% fluorescent-labeled <i>SARS-CoV-2</i> , <i>Influenza A</i> , <i>Influenza B</i> and Internal Control probes, 0.004% Taq DSC 2.0 DNA polymerase, 0.01% ProClin® 300 preservative ^b	EUH210 Safety data sheet available on request. EUH208 Contains reaction mass of: 5-chloro-2-methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3-one [EC no. 220-239-6] (3:1). May produce an allergic reaction.

^a Product safety labeling primarily follows EU GHS guidance

^b Hazardous substance or mixture

Table 2: cobas® SARS-CoV-2 & Influenza A/B Quality Control Kit

cobas® SARS-CoV-2 & Influenza A/B Quality Control Kit Store at 2-8°C (P/N 09211128190) 11 transfer pipettes 1 Control Kit Barcode Card			
Kit components	Reagent ingredients	Quantity per kit	Safety symbol and warning ^a
cobas® SARS-CoV-2 & Influenza A/B Positive Control SARS-CoV-2 (+) C (P/N 09212078001)	Tris buffer, EDTA, < 0.003% Poly rA (synthetic), < 0.01% non-infectious plasmid DNA (microbial) containing SARS-CoV-2 sequence, < 0.05% sodium azide	3 X 0.25 mL	N/A
cobas® SARS-CoV-2 & Influenza A/B Positive Control FLU A/B (+) C (P/N 07758448001)	Magnesium chloride, polyethylene glycol, bovine serum albumin, phosphate buffer saline, < 0.01% Poly rA, (synthetic), 5% non-infectious influenza AH1 stock and 1% Non-infectious influenza B stock (micro-organism purified and chemically inactivated), < 0.01% ProClin® 300 preservative ^b , Phenol red	3 X 10 µL	 EUH210 Safety data sheet available on request. EUH208 Contains reaction mass of: 5-chloro-2- methyl-4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol-3- one [EC no. 220-239-6] (3:1). May produce an allergic reaction.
cobas® Dilution UTM Dilution UTM (-) C (P/N 08053669001)	N/A	3 X 0.3 mL	N/A

^aProduct safety labeling primarily follows EU GHS guidance^bHazardous substance or mixture

Reagent storage and handling

Reagents shall be stored and will be handled as specified in Table 3.

Do not freeze materials listed below. Do not open individual assay tube packaging until operator is ready to perform testing.

Table 3: Reagent storage and handling

Reagent	Storage Temperature	Storage Time
cobas® SARS-CoV-2 & Influenza A/B	2-8°C	Stable until the expiration date indicated
cobas® SARS-CoV-2 & Influenza A/B Quality Control Kit	2-8°C	Stable until the expiration date indicated

Additional materials required

Table 4: Materials required but not provided

Specimen Collection Kit	P/N
Nasopharyngeal Swab Collection Kits: Flexible minitip FLOQSwab™ with Universal Transport Media™ (UTM®) from Copan Diagnostics OR BD™ Universal Viral Transport (UVT) 3-mL collection kit with a flocced flexible minitip swab	305C 220531
Nasal Swab Collection Kits: Regular FLOQSwab™ with Universal Transport Media™ (UTM®) from Copan Diagnostics OR BD™ Universal Viral Transport (UVT) 3-mL collection kit with a regular flocced swab Copan Universal Transport Medium (UTM-RT®), without beads	306C 220528 3C047N
Thermo Fisher™ Scientific Remel™ M4RT Thermo Fisher™ Scientific Remel™ M4 Thermo Fisher™ Scientific Remel™ M5 Thermo Fisher™ Scientific Remel™ M6 Thermo Fisher™ Scientific Remel™ M4RT® tube, without beads	R12565, R12566, R12567 R12550 R12555 R12563, R12568, R12569 R12622, R12591

Instrumentation and software required

The **cobas®** Liat® System Software is installed on the instrument(s).

Table 5: Equipment and software required but not provided

Equipment and Software
cobas® Liat® Analyzer (P/N 07341920190) Including cobas® Liat® System Software (Core) Version 3.2 or higher
cobas® SARS CoV-2 & Influenza A/B Assay Script v1.0 or higher

Note: For additional information regarding the **cobas®** Liat® Analyzer, please refer to the **cobas®** Liat® System User Guide (if software version 3.2, refer to Operator's Manual).

Precautions and handling requirements

Warnings and precautions

- For *in vitro* diagnostic use.
- Before using **cobas®** SARS-CoV-2 & Influenza A/B, operator should carefully read Instructions For Use (IFU) and the **cobas®** Liat® System User Guide (if software version 3.2, refer to Operator's Manual).

- Treat all biological specimens, including used **cobas**® SARS-CoV-2 & Influenza A/B assay tubes and transfer pipettes, as if capable of transmitting infectious agents. It is often impossible to know which specimens might be infectious; all biological specimens should be treated with universal precautions. Guidelines for specimen handling are available from the U.S. Centers for Disease Control and Prevention, Clinical and Laboratory Standards Institute and World Health Organization.¹³⁻¹⁷
- Follow your institution's safety procedures for working with chemicals and handling biological samples.
- If infection with a novel influenza A virus is suspected based on current clinical and epidemiological screening criteria recommended by public health authorities, specimens should be collected using appropriate infection control precautions for novel virulent influenza viruses and sent to local health departments for testing. Virus culture should not be attempted in these cases unless a BSL-3 facility is available to receive and culture specimens.
- Do not use a damaged **cobas**® SARS-CoV-2 & Influenza A/B assay tube.
- Do not use a **cobas**® SARS-CoV-2 & Influenza A/B assay tube that has been dropped after removal from its foil pouch.
- Do not open the cap of the **cobas**® SARS-CoV-2 & Influenza A/B assay tube during or after the run on the **cobas**® Liat Analyzer.
- For additional warnings, precautions and procedures to reduce the risk of contamination for the **cobas**® Liat® Analyzer, consult the **cobas**® Liat® System User Guide (if software version 3.2, refer to Operator's Manual).
- Dispose of a used **cobas**® SARS-CoV-2 & Influenza A/B assay tube, pipette and specimen tube according to your institution's safety guidelines for hazardous material.
- On request Safety Data Sheets (SDS) are available from your local Roche representative.
- Due to the high sensitivity of the assays run on the **cobas**® Liat® Analyzer, contamination of the work area with previous positive samples may cause false positive results. Handle samples according to standard laboratory practices. Clean instruments and surrounding surfaces according to instructions provided in the cleaning section of the **cobas**® Liat® System User Guide (if software version 3.2, refer to Operator's Manual). If spills occur on the **cobas**® Liat® Analyzer, follow the appropriate instructions in the **cobas**® Liat® System User Guide (if software version 3.2, refer to Operator's Manual) to clean.
- Specimen collection must be performed using the recommended swab types. Inadequate or inappropriate sample collection, storage, and transport may yield incorrect or invalid test results. DO NOT use cotton or calcium alginate swabs, or swabs with wood shafts.
- When using 0.9% physiological saline solution, ensure that the swab height is appropriate for the collection and the score mark is not higher than the height of the collection tube.
- Ensure there is no sign of leakage from the collection tube prior to running the test.
- Use only the transfer pipettes contained in the **cobas**® SARS-CoV-2 & Influenza A/B assay pack and **cobas**® SARS-CoV-2 & Influenza A/B Quality Control Kit. Use of alternative transfer pipettes may lead to invalid results.
- Good laboratory practices and careful adherence to the procedures specified in this Instructions For Use document are necessary. Wear laboratory gloves, laboratory coats, and eye protection when handling samples and reagents. Gloves must be changed between handling samples and **cobas**® SARS-CoV-2 & Influenza A/B assay tube, **cobas**® SARS-CoV-2 Quality Control Kit to avoid contamination of reagents.
- After handling samples and kit reagents, remove gloves and wash hands thoroughly.

Sample collection, transport, and storage

Note: Handle all samples and controls as if they are capable of transmitting infectious agents. Do not use cotton or calcium alginate swab, or swab with wood shafts.

Sample collection

- Collect specimen using a sterile flocked swab with a synthetic tip (e.g., Dacron, nylon, or rayon) according to applicable manufacturer instructions and/or standard collection technique using 3 mL of viral transport media. If the viral transport media listed in Table 4 are not available an alternative 0.9% physiological saline solution can be used.
- Collect nasopharyngeal and nasal swab samples following standard collection technique and immediately place in pre-measured 3 mL of 0.9% physiological saline solution.

Transport and storage

Transportation of collected specimens must comply with all applicable regulations for the transport of etiologic agents.

Transport and test specimens as soon as possible after collection.

- If transportation is required, specimens must be packaged, shipped, and transported according to the current edition of the International Air Transport Association (IATA) Dangerous Goods Regulation. Follow shipping regulations for UN 3373 Biological Substance, Category B when sending potential SARS-CoV-2 or influenza virus specimens. Store specimens at 2-8°C and ship overnight on ice pack. If a specimen is frozen at $\leq -70^{\circ}\text{C}$, ship overnight on dry ice.
- Specimen transferred into the cobas® SARS-CoV-2 & Influenza A/B assay tube should be run as soon as possible on the Analyzer. Once the sample has been added to the cobas® SARS-CoV-2 & Influenza A/B assay tube it may be stored at room temperature for up to 4 hours.
- Specimens collected in transport media (UTM-RT® or UVT, M4, M4RT, M5 and M6) may be stored up to 4 hours at room temperature or up to 72 hours at 2-8°C if immediate testing is not possible. Freezing at -70°C or colder (and transportation on dry ice) is required for specimen storage or transportation beyond 72 hours prior to the specimen being added to the assay tube for testing.
- Specimens collected in 0.9% physiological saline solution may be stored up to 4 hours at room temperature or up to 72 hours at 2-8°C if immediate testing is not possible.

Instructions for use

Procedural notes

- Do not use cobas® SARS-CoV-2 & Influenza A/B assay tube and cobas® SARS-CoV-2 & Influenza A/B Quality Control Kit after their expiry dates.
- Do not reuse assay tubes and transfer pipettes. They are for one-time use only.
- Refer to the cobas® Liat® System User Guide (if software version 3.2, refer to Operator's Manual) for detailed operation and routine cleaning of instruments.

Running cobas® SARS-CoV-2 & Influenza A/B

Use the transfer pipette to load approximately 0.2 mL of the specimen into the cobas® SARS-CoV-2 & Influenza A/B assay tube. cobas® Liat® Analyzer will adjust the sample volume if more sample was loaded.

Always use caution when transferring specimens from a sample collection tube to the assay tube.

Use transfer pipettes included in the kit to handle specimens.

Always use a new transfer pipette for each specimen.

The test procedure is described in detail in the cobas® Liat® System User Guide (if software version 3.2, refer to Operator's Manual). Figure 1 below summarizes the procedure.

Test procedure

Figure 1: cobas® SARS-CoV-2 & Influenza A/B procedure

“Lot Validation” workflow

1	Start up the system and login
2	Obtain Controls and assay tubes
3	Under “Assay” menu, choose “New Lot”
4	Scan the barcode on the Package Insert ID Barcode card
5	Scan and run Negative Control
6	Scan and run Positive Control

cobas® SARS CoV-2 & Influenza A/B workflow

1	Start up the system and login
2	Obtain samples and assay tubes
3	On the Main Menu, choose “Run Assay”
4	Scan cobas ® SARS-CoV-2 & Influenza A/B assay tube barcode
5	Scan or enter sample ID
6	Add specimen to cobas ® SARS-CoV-2 & Influenza A/B assay tube using transfer pipette and re-cap the tube
7	Re-scan cobas ® SARS-CoV-2 & Influenza A/B assay tube barcode
8	Start run
9	Review results*
10	Unload and dispose used cobas ® SARS-CoV-2 & Influenza A/B assay tube

* Refer to **cobas**® Liat® System User Guide (if software version 3.2, refer to Operator's Manual) for details of result uploading to LIS.

cobas® SARS-CoV-2 & Influenza A/B assay tube Lot Validation

Before using a new lot of cobas® SARS-CoV-2 & Influenza A/B assay tubes, a Lot Validation procedure must be performed on the cobas® Liat® Analyzer to validate the cobas® SARS-CoV-2 & Influenza A/B assay tube lot at your site. The procedure includes running a Negative Control sample and a Positive Control sample.

Note: Refer to the cobas® Liat® System User Guide (if software version 3.2, refer to Operator's Manual) for detailed operating instructions.

Materials needed for Lot Validation

From cobas® SARS-CoV-2 & Influenza A/B assay tube Kit:

- Package Insert ID Barcode Card: contained in the cobas® SARS-CoV-2 & Influenza A/B assay tube Kit. This barcode is lot-specific; match the lot number next to the barcode with the lot number on the cobas® SARS-CoV-2 & Influenza A/B assay tubes.
- 2 cobas® SARS-CoV-2 & Influenza A/B assay tubes
- 2 transfer pipettes

From cobas® SARS-CoV-2 & Influenza A/B Quality Control Kit:


- Negative Control: Negative Control Barcode (see Control Kit Barcode Card), 1 Dilution UTM-RT® tube (used as the negative control sample)
- Positive Control: Positive Control Barcode (see Control Kit Barcode Card), 1 cobas® SARS-CoV-2 Positive Control tube, 1 cobas® Influenza A/B Positive Control tube
- 1 transfer pipette

Prepare and test Negative Control sample

Materials needed:

- Package Insert Barcode on the Package Insert Barcode Card contained in the cobas® SARS-CoV-2 & Influenza A/B assay tube Kit
- Negative Control Barcode on the Control Kit Barcode Card
- 1 Dilution UTM-RT® tube
- 1 cobas® SARS-CoV-2 & Influenza A/B assay tube from this lot
- 1 transfer pipette

Note: Following Figure 2, match the lot number (L/N) of the Dilution UTM-RT® tube label to the lot number (LOT) of the Negative Control Barcode Label on the Control Kit Barcode Card, and then use the Negative Control Barcode (on the Control Kit Barcode Card) as the sample ID when performing negative control run.

Figure 2: Schematic diagram for illustrating Negative Control tube and Control Kit Barcode Card

Assay tube Lot Validation workflow

1. Press the power on/off button to start the **cobas®** Liat® Analyzer.
2. Select “**Login**” on the screen of the **cobas®** Liat® Analyzer.
3. Enter user name when prompted, select “**OK**”.
4. Enter user password when prompted, select “**OK**”.

Note: You may be prompted to confirm you have read the User Manual (i.e., **cobas®** Liat® System User Guide or Operator’s Manual).

5. Select “**Assay Menu**” on the main menu of a **cobas®** Liat® Analyzer.
6. Select “**New Lot**” at the bottom of the list.
7. When prompted to **Scan the Insert ID**, select “**Scan**” and scan the **cobas®** SARS-CoV-2 & Influenza A/B Package Insert ID Barcode card. Ensure that the red scan light is over the entire barcode.

Note: You may be prompted to confirm you have read Instructions For Use.

8. When prompted to **scan the Negative Control ID**, select “**Scan**” and scan the Negative Control Barcode card included with the control kit. Ensure that the red scan light is over the entire barcode. Next, the **cobas®** Liat® Analyzer will prompt with the message “**Add negative control & scan tube ID**”.
9. Hold a tube of Negative Control upright and lightly tap on a flat surface to collect liquid at the bottom of the tube. Visually check that the Dilution UTM-RT® has pooled at the bottom of the tube.
10. Open up a **cobas®** SARS-CoV-2 & Influenza A/B assay tube foil pouch (from the lot to be added) and remove the contents.

11. Use the transfer pipette provided in the pouch to add the Negative Control to the cobas® SARS-CoV-2 & Influenza A/B assay tube. Firmly squeeze the bulb of the pipette until the bulb is fully flat, then insert the tip of the pipette into the liquid and draw up the sample by slowly releasing the bulb.

Note: *Only use the transfer pipette provided in the cobas® SARS-CoV-2 & Influenza A/B assay tube pouch to transfer controls and samples into the cobas® SARS-CoV-2 & Influenza A/B assay tube.*

12. Carefully remove the cap of the cobas® SARS-CoV-2 & Influenza A/B assay tube and insert the pipette into the opening. Place the pipette tip near the bottom of the open segment.
13. Slowly squeeze the bulb to empty the contents of the pipette into the cobas® SARS-CoV-2 & Influenza A/B assay tube. Avoid creating bubbles in the sample. Do not release the pipette bulb while the pipette is still in the cobas® SARS-CoV-2 & Influenza A/B assay tube.

Note: *Do not puncture the cobas® SARS-CoV-2 & Influenza A/B assay tube or the seal at the bottom of the sample compartment. If either of these are damaged, discard both the cobas® SARS-CoV-2 & Influenza A/B assay tube and the transfer pipette, and restart the testing procedure with a new cobas® SARS-CoV-2 & Influenza A/B assay tube and pipette.*

14. Screw the cap back onto the cobas® SARS-CoV-2 & Influenza A/B assay tube. Dispose of the transfer pipette as biohazardous material.
15. Select “Scan” and place the cobas® SARS-CoV-2 & Influenza A/B assay tube horizontally on the table beneath the barcode reader so that the red scan light is over the entire barcode. The tube entry door on top of the cobas® Liat® Analyzer will open automatically once the barcode is read.
16. Remove the cobas® SARS-CoV-2 & Influenza A/B assay tube sleeve and immediately insert the cobas® SARS-CoV-2 & Influenza A/B assay tube into the cobas® Liat® Analyzer until the tube clicks into place.

Note: *The cobas® SARS-CoV-2 & Influenza A/B assay tube only fits in one way - the grooved side of the cobas® SARS-CoV-2 & Influenza A/B assay tube must be on the left while the cap is on top.*

17. If the tube is not inserted by the time the door closes, re-scan the cobas® SARS-CoV-2 & Influenza A/B assay tube barcode and insert the cobas® SARS-CoV-2 & Influenza A/B assay tube again. Once the cobas® SARS-CoV-2 & Influenza A/B assay tube is properly inserted, the cobas® Liat® Analyzer will close the door automatically and begin the test.
18. During the test, the cobas® Liat® Analyzer displays the running status and estimated time remaining. Once the test is complete, the cobas® Liat® displays the message, “Remove tube slowly and carefully.” and opens the tube entry door automatically. Slowly lift the cobas® SARS-CoV-2 & Influenza A/B assay tube out of the cobas® Liat® Analyzer. Dispose of the used cobas® SARS-CoV-2 & Influenza A/B assay tube as biohazardous material.
19. If “Negative control result accepted.” is displayed at the end of the run, select “Confirm” (If software version 3.2, select “OK”). If the result is rejected, repeat the negative control run (steps 8-19). If repeated control runs do not produce the expected results, contact your local Roche representative.
20. Select “Confirm” (If software version 3.2, select “Back”) to proceed with the cobas® SARS-CoV-2 & Influenza A/B Positive Control test on the same instrument.
21. Prepare positive control sample as follows.


Prepare cobas® SARS-CoV-2 & Influenza A/B Positive Control sample and continue with Lot Validation

Materials needed:

- 1 transfer pipette (Use only transfer pipettes contained in the **cobas®** SARS-CoV-2 & Influenza A/B Quality Control Kit)
- 1 **cobas®** SARS-CoV-2 Positive Control
- 1 **cobas®** Influenza A/B Positive Control (pellet comprising dried positive control material at bottom of tube)

Note: Prior to resuspending the Positive control, match the lot numbers (L/N) of the Positive Control tube label for **cobas®** SARS-CoV-2 & **cobas®** Influenza A/B to the lot number (LOT) of the Positive Control Barcode Label on the Control Kit Barcode Card as shown in Figure 3. Use the Positive Control Barcode (on the Control Kit Barcode Card) as the sample ID when performing positive control run.

Figure 3: Schematic diagram illustrating **cobas®** SARS-CoV-2 & **cobas®** Influenza A/B Positive Control tubes and Control Kit Barcode Card



1. After opening **cobas®** Influenza A/B Positive Control pouch, discard desiccant packet.
2. After opening **cobas®** SARS-CoV-2 Positive Control pouch, hold the tube upright and lightly tap on a flat surface to collect liquid at the bottom of the vial. Visually check that the liquid has pooled at the bottom of the tube.
3. Use the provided transfer pipette to transfer approximately 0.2 mL of the liquid from the **cobas®** SARS-CoV-2 Positive Control to the **cobas®** Influenza A/B Positive Control tube.
 - a) Check that the **cobas®** Influenza A/B Positive Control pellet is at the bottom of the tube prior to addition of the **cobas®** SARS-CoV-2 Positive Control. Do not use the **cobas®** Influenza A/B Positive Control if a pellet is not visible prior to rehydration.

- b) Squeeze the pipette bulb until the bulb is fully flat. While holding the bulb fully flat, insert the pipette tip into the liquid just below the liquid surface in the **cobas®** SARS-CoV-2 Positive Control tube.
 - c) Slowly release the bulb completely while keeping the pipette tip below the liquid surface. You will see the liquid rising into the pipette. After releasing the bulb completely, withdraw the pipette from the **cobas®** SARS-CoV-2 Positive Control vial. A small volume of liquid may remain in the tube after the bulb is fully released.
 - d) Insert pipette into the **cobas®** Influenza A/B Positive Control tube until the tip is at the bottom of the tube.
 - e) Slowly squeeze the bulb to empty the contents of pipette. Avoid creating bubbles in the sample. Do not release the pipette bulb.
 - f) While still squeezing the pipette bulb, withdraw the pipette from the tube. Dispose of the **cobas®** SARS-CoV-2 Positive Control tube and transfer pipette according to your institution's guidelines for safe disposal of hazardous material. Do not reuse transfer pipettes.
 - g) Cap the **cobas®** Influenza A/B Positive Control tube. Hold the **cobas®** Influenza A/B Positive Control tube by the cap and shake down the liquid in the tube using a quick, sharp, downward wrist motion.
4. Let the **cobas®** Influenza A/B Positive Control tube sit for 5 minutes to begin dissolving the dried material.
 5. After the Positive Control tube has sat for 5 minutes, use another transfer pipette from the **cobas®** SARS-CoV-2 & Influenza A/B Quality Control kit to slowly pipette the sample up and down 10 times to dissolve and mix the positive control sample. Avoid generating bubbles. Re-cap the **cobas®** Influenza A/B Positive Control tube and dispose of the transfer pipette as biohazardous material.
 6. Similarly, follow **Lot Validation** workflow steps **8** to **19** with the resuspended **cobas®** SARS-CoV-2 & Influenza A/B Positive Control in place of the Negative Control.
 7. If **“Positive control result accepted.”** is displayed at the end of the run, select **“Confirm”** (If software version 3.2, select **“OK”**) and then select **“Back”** to return to Main menu. If the result is rejected, repeat the **cobas®** SARS-CoV-2 & Influenza A/B Positive Control test. If repeated control runs do not produce the expected results, contact your local Roche representative.
 8. Select **“Assay Menu”** to verify that the new lot has been added.

Transferring assay tube lot information

After Lot Validation workflow is completed on one Analyzer, use the Advanced Tools (If software version 3.2, Advanced Tools Key) to transfer the lot information to the other Analyzers at your site. This allows the other Analyzers to use this **cobas®** SARS-CoV-2 & Influenza A/B assay tube lot without performing Lot Validation on each Analyzer. Consult the software specific Advanced Tools guide for details of operation.

cobas® SARS-CoV-2 & Influenza A/B on clinical specimens testing

Material needed for running cobas® SARS-CoV-2 & Influenza A/B

- **cobas®** SARS-CoV-2 & Influenza A/B assay foil pouch which includes the **cobas®** SARS-CoV-2 & Influenza A/B assay tube
- 1 transfer pipette
- 1 specimen in collection media

Procedure

1. Ensure that the **cobas**® Liat® Analyzer is powered on.
2. Select “**Login**” on the screen of the **cobas**® Liat® Analyzer.
3. Enter user name when prompted, select “**OK**”.
4. Enter user password when prompted, select “**OK**”.

Note: You may be prompted to confirm you have read the User Manual (i.e., **cobas**® Liat® System User Guide or Operator’s Manual).

5. From the Main Menu, select “**Run Assay**”.
6. Open up a **cobas**® SARS-CoV-2 & Influenza A/B assay tube pouch and take out the assay tube. When prompted to **scan Liat Tube ID**, select “**Scan**” and place the SARS-CoV-2 & Influenza A/B assay tube horizontally on the table beneath the barcode reader so that the red scan light is over the entire barcode.
7. When prompted to **scan the sample ID**, select “**Scan**” to scan the sample barcode. In the case that the sample cannot be scanned, select “**Enter**” to manually enter the sample ID.
 - a. **Note:** If patient verification is activated, the Analyzer will display the status of verification.
 - i. If patient verification is successful, the Analyzer may prompt confirmation of entered information before proceeding with running the assay.
 - ii. If patient verification fails, the Analyzer may display a notification that verification failed:
 1. And may require acknowledgement before proceeding with running the assay or
 2. If unable to proceed with running the assay contact your lab administrator.
8. When prompted to add the sample, use the transfer pipette provided in the assay tube pouch to transfer specimen. Firmly squeeze the bulb of the pipette until the bulb is fully flat, then insert the tip of the pipette into the liquid and draw up the sample by slowly releasing the bulb.
9. Carefully remove the cap of the **cobas**® SARS-CoV-2 & Influenza A/B assay tube and insert the pipette into the opening. Place the pipette tip near the bottom of the open segment.
10. Slowly squeeze the bulb to empty the contents of the pipette into the **cobas**® SARS-CoV-2 & Influenza A/B assay tube. Do not release the pipette bulb while the pipette is still in the **cobas**® SARS-CoV-2 & Influenza A/B assay tube.

Note: Do not puncture the **cobas**® SARS-CoV-2 & Influenza A/B assay tube or the seal at the bottom of the sample compartment. If either of these are damaged, discard both the **cobas**® SARS-CoV-2 & Influenza A/B assay tube and the transfer pipette, and restart the testing procedure with a new **cobas**® SARS-CoV-2 & Influenza A/B assay tube and pipette.

11. Re-cap the **cobas**® SARS-CoV-2 & Influenza A/B assay tube and dispose of the transfer pipette as biohazardous material.

Note: Avoid contaminating gloves, equipment and work surfaces with the residual contents of the pipette.

12. Select “**Scan**” and rescan the same **cobas**® SARS-CoV-2 & Influenza A/B assay tube barcode. The tube entry door on top of the **cobas**® Liat® Analyzer will open automatically.

13. Remove the **cobas**® SARS-CoV-2 & Influenza A/B assay tube sleeve and immediately insert the **cobas**® SARS-CoV-2 & Influenza A/B assay tube into the **cobas**® Liat® Analyzer until the tube clicks into place.

Note: *The SARS-CoV-2 & Influenza A/B assay tube only fits in one way - the grooved side of the cobas® SARS-CoV-2 & Influenza A/B assay tube must be on the left while the cap is on top.*

14. If the assay tube is not inserted by the time the door closes, re-scan the **cobas**® SARS-CoV-2 & Influenza A/B assay tube barcode and insert the **cobas**® SARS-CoV-2 & Influenza A/B assay tube again. Once the **cobas**® SARS-CoV-2 & Influenza A/B assay tube is properly inserted, the **cobas**® Liat® Analyzer will close the door automatically and begin the test.
15. During the test, the **cobas**® Liat® Analyzer displays the running status and estimated time remaining. Once the test is complete, the **cobas**® Liat® Analyzer displays the message, “Remove tube slowly and carefully.” and opens the tube entry door automatically. Slowly lift the **cobas**® SARS-CoV-2 & Influenza A/B assay tube out of the **cobas**® Liat® Analyzer. Dispose of the used **cobas**® SARS-CoV-2 & Influenza A/B assay tube as biohazardous material.
16. Select “**Report**” to see the Result Report. If applicable, select “**Print**” to print the report.
17. Select “**Back**”, and then “**Main**” to return to the main menu to perform the next test.

Performing additional control runs

In accordance with local, state, federal and/or accrediting organization requirements, additional control runs may be performed with a lot of **cobas**® SARS-CoV-2 & Influenza A/B assay tubes that has already been added through the “Lot Validation” workflow. Use the **cobas**® SARS-CoV-2 & Influenza A/B Quality Control Kit for use on the **cobas**® Liat® System to conduct these runs.

Materials needed for additional control runs

- **cobas**® SARS-CoV-2 & Influenza A/B assay tubes
- 1 Transfer pipette
- **cobas**® Liat® SARS-CoV-2 & Influenza A/B Positive Controls and/or Negative Control
- Corresponding barcodes for the **cobas**® SARS-CoV-2 & Influenza A/B Positive Controls and/or the Negative Control

Procedure

Use the procedure outlined under the section “**cobas**® SARS-CoV-2 & Influenza A/B on clinical specimens testing” to perform additional control runs. In step 7, be sure to use the provided control barcodes included in **cobas**® SARS-CoV-2 & Influenza A/B Control Kit to scan as sample ID barcode. Interpretation of results for **cobas**® SARS-CoV-2 & Influenza A/B when running additional **cobas**® SARS-CoV-2 & Influenza A/B Positive Controls or Negative Controls are shown in the “Interpretation of results” section (Table 6 through Table 8). Using barcodes other than the control barcodes provided may lead to incorrect control results.

Results

Quality control and interpretation of results

Table 6: Interpretation of results of cobas® SARS-CoV-2 & Influenza A/B when running “Lot Validation” procedure

cobas® Liat® Analyzer Display	Interpretation
Negative Control Valid	Negative Control Valid Control is negative for the presence of SARS-CoV-2, influenza type A virus and influenza type B virus RNA.
Negative Control Invalid. Repeat Run	Negative Control Invalid Result is Invalid. The Negative Control should be re-tested to obtain valid result. Repeat Run.
Positive Control Valid	Positive Control Valid Control is positive for the presence of SARS-CoV-2, influenza type A virus and influenza type B virus RNA.
Positive Control Invalid. Repeat Run	Positive Control Invalid Result is Invalid. The positive control should be re-tested to obtain valid result. Repeat Run.

Note: If the repeated run is still invalid, contact your local Roche representative.

Table 7: Interpretation of results of **cobas®** SARS-CoV-2 & Influenza A/B when running a sample

Result Report		Interpretation
SARS-CoV-2	SARS-CoV-2 Not Detected	Negative test for SARS-CoV-2 (no SARS-CoV-2 RNA detected)
	SARS-CoV-2 Detected	Positive test for SARS-CoV-2 (SARS-CoV-2 RNA present)
	SARS-CoV-2 Invalid	Presence or absence of SARS-CoV-2 cannot be determined. If clinically indicated, repeat assay with same sample or, if possible, collect new sample for testing.
Influenza A	Influenza A Not Detected	Negative test for influenza A (no Influenza A RNA detected)
	Influenza A Detected	Positive test for influenza A (Influenza A RNA present)
	Influenza A Invalid	Presence or absence of influenza A cannot be determined. If clinically indicated, repeat assay with same sample or, if possible, collect new sample for testing.
Influenza B	Influenza B Not Detected	Negative test for influenza B (no Influenza B RNA detected)
	Influenza B Detected	Positive test for influenza B (Influenza B RNA present)
	Influenza B Invalid	Presence or absence of influenza B cannot be determined. If clinically indicated, repeat assay with same sample or, if possible, collect new sample for testing.
Assay Invalid		Presence or absence of SARS-CoV-2, influenza A, and influenza B cannot be determined. Repeat assay with same sample or, if possible, collect new sample for testing.
[Error]. Assay Aborted		Presence or absence of SARS-CoV-2, influenza A, and influenza B cannot be determined. Repeat assay with same sample or, if possible, collect new sample for testing.

Table 8: Interpretation of results when running additional controls after following “Lot Validation” procedure**Positive control**

cobas® Liat® Analyzer Display	Interpretation
Positive Control Valid	Positive Control Valid Control is positive for the presence of SARS-CoV-2 virus, influenza type A virus, and influenza type B virus RNA.
Positive Control Invalid	Positive Control Invalid Result is Invalid. The Positive Control should be re-tested to obtain valid result. Repeat Run.

Note: If the repeated run is still invalid, contact your local Roche representative.

Negative control

cobas® Liat® Analyzer Display	Interpretation
Negative Control Valid	Negative Control Valid Control is negative for the presence of SARS-CoV-2 virus, influenza type A virus and influenza type B virus RNA.
Negative Control Invalid	Negative Control Invalid Result is Invalid. The Negative Control should be re-tested to obtain valid result. Repeat Run.

Note: If the repeated run is still invalid, contact your local Roche representative.

Procedural limitations

- **cobas® SARS-CoV-2 & Influenza A/B** has been evaluated only for use in combination with the **cobas® SARS-CoV-2 & Influenza A/B Quality Control Kit** and this Instructions For Use document. Modifications to these procedures may alter the performance of the test.
- Due to inherent differences between technologies, it is recommended that, prior to switching from one technology to the next, users perform method correlation studies in their laboratory to qualify technology differences. One hundred percent agreement between the results should not be expected due to aforementioned differences between technologies. Users should follow their own specific policies/procedures.
- This test is intended to be used for the detection of SARS-CoV-2, Influenza A and Influenza B RNA in nasal and nasopharyngeal swab samples collected in a Copan UTM-RT System (UTM-RT®) or BD™ Universal Viral Transport System (UVT) or Thermo Fisher™ Scientific Remel™ media, or 0.9% physiological saline solution. Testing of other sample or media types may lead to inaccurate results.
- As with other tests, negative results do not preclude SARS-CoV-2, Influenza A or Influenza B, infection and should not be used as the sole basis for treatment or other patient management decisions.
- False negative results may occur if a specimen is improperly collected, transported or handled, if there is insufficient RNA to be detected, or if one or more target viruses inhibits amplification of other targets.
- Invalid results may be obtained if there is insufficient sample volume or if the specimen contains inhibitory substances that prevent nucleic acid target extraction and/or amplification and detection.
- Mutations within the target regions of **cobas® SARS-CoV-2**, Influenza A, and Influenza B could affect primer and/or probe binding that results in failure to detect the presence of virus.
- False negative or invalid results may occur due to interference. The Internal Control is included in **cobas® SARS-CoV-2 & Influenza A/B** to help identify the specimens containing substances that may interfere with nucleic acid isolation and PCR amplification.
- Results from analytical studies show potential for competitive inhibition of lower titer influenza in specimens with higher titer SARS-CoV-2 also present. Consider further investigation of negative influenza results if a co-infection is suspected and detection of influenza would change clinical management.
- ~~□ The performance of this device has not been assessed in a population vaccinated against COVID-19.~~
-

Non-clinical performance – SARS-CoV-2

Key performance characteristics

The **cobas**® SARS-CoV-2 & Influenza A/B assay was developed by mainly replacing the RSV primers and probes with those required to detect the SARS-CoV-2 targets in the existing **cobas**® Influenza A/B & RSV assay. The original studies of the **cobas**® Influenza A/B & RSV assay remain relevant for the performance of Influenza A/B targets in the **cobas**® SARS-CoV-2 & Influenza A/B assay.

Analytical sensitivity

Limit of detection (LoD) studies determine the lowest detectable concentration of SARS-CoV-2 at which greater or equal to 95% of all (true positive) replicates test positive.

To determine the LoD for SARS-CoV-2, a heat inactivated cultured virus of an isolate from a US patient (USA-WA1/2020, lot number 324047, 3.16E+06 TCID₅₀/mL, ZeptoMetrix, NY, USA) was serially diluted in pooled negative nasopharyngeal swab matrix. Five concentration levels were tested with 20 replicates except for the highest concentration level, which was tested with 10 replicates. Three lots of assay tubes (approximately equal numbers of replicates per lot), and two independent dilution series (equal numbers of replicates per dilution series) were used in the study.

As shown in Table 9, the concentration level with observed hit rates greater than or equal to 95% was 0.012 TCID₅₀/mL (12 copies/mL) for SARS-CoV-2. As shown in Table 10, the Probit predicted 95% hit rate was 0.010 TCID₅₀/mL for SARS-CoV-2.

Table 9: LoD Determination Using USA-WA1/2020 Strain

Strain	Concentration [TCID ₅₀ /mL]	Concentration [copies/mL]	Total valid results	Hit rate [%]	Mean Ct*
USA-WA1/2020 (stock concentration 3.16E+06 TCID ₅₀ /mL)	0.048	49	10	100	32.6
	0.024	24	20	100	33.5
	0.012	12	20	100	35.2
	0.006	6	20	70	35.9
	0.003	3	20	25	36.7

* Calculations only include positive results.

Table 10: Probit predicted 95% Hit Rates Using USA-WA1/2020 strain

Strain	Probit Predicted 95% Hit Rate [TCID ₅₀ /mL]
USA-WA1/2020 (stock concentration 3.16E+06 TCID ₅₀ /mL)	0.010 (95% CI: 0.007 – 0.018)

Reactivity/inclusivity

In silico analysis concluded that cobas® SARS-CoV-2 & Influenza A/B will detect all analyzed SARS-CoV-2 sequences in NCBI and GISAID databases by using a dual target design (Table 11). Less than 1.44% of sequences analyzed had non-significant mismatches in the RdRp gene, of which all had 100% perfect match in the N gene. Conversely, less than 0.69% of sequences analyzed had non-significant mismatches in the N gene, of which all had 100% perfect match in the RdRp gene. One sequence was identified that had three mismatches close to the 5'-end of the probe binding region of N gene detection set. This sequence had 100% perfect match to the RdRp detection set, therefore no impact on assay performance is expected.

Table 11: *In silico* inclusivity analysis of SARS-CoV-2

Target	RdRp gene (ORF1ab)				N gene			
Database	NCBI		GISAID		NCBI		GISAID	
Number of Sequences	3552	100%	27350	100%	3342	100%	27175	100%
Sequences with mutation	51	1.44%	119	0.44%	23	0.69%	142	0.52%
Predicted no detection	0	0.00%	0	0.00%	0	0.00%	1	0.004%

Cross reactivity- *In Silico* Analysis

The *in silico* analysis for possible cross reactions with all the organisms listed in was conducted by mapping binding regions of the primers and probes in cobas® SARS-CoV-2 & Influenza A/B to the sequences available from NCBI and GISAID databases. The percent homology of sequences that partially aligned with the SARS-CoV-2 N and RdRp targets is shown in the table below. If any two of the primers were mapped to a sequence on opposite strands with short distance apart, potential amplifications were flagged. No potential unintended cross reactivity is expected based on this *in silico* analysis except for SARS-CoV-1 which has been additionally tested as shown in Table 12.

Table 12: Organisms with homology to SARS-CoV-2 N and RdRp primers and probes

Strain	Percent homology to N			Percent Homology to RdRp		
	Forward primer	Probe	Reverse primer	Forward primer	Probe	Reverse primer
Human coronavirus HKU1	-	-	-	-	-	81.50%
SARS-coronavirus (SARS-CoV-1)	100.00%	81.48%	94.74%	95.80%	87.50%	96.30%
MERS-coronavirus	80.00%	-	-	-	-	-
Haemophilus influenzae	95.00%	-	-	-	-	-
Legionella pneumophila	80.00%	-	-	-	-	-
Streptococcus pyogenes	80.00%	-	-	-	-	-
Mycoplasma pneumoniae	-	-	-	83.30%	-	-
Candida albicans	90.00%	-	-	83.30%	-	-
Staphylococcus epidermidis	85.00%	-	-	-	-	-
Staphylococcus salivarius	-	-	89.47%	-	-	-
Human coronavirus 229E/OC43/NL63	No alignment found*			No alignment found*		
Adenovirus (e.g., C1 Ad. 71)	No alignment found*			No alignment found*		
Human metapneumovirus (hMPV)	No alignment found*			No alignment found*		
Influenza A (all available sequences)	No alignment found*			No alignment found*		
Influenza B (all available sequences)	No alignment found*			No alignment found*		
Enterovirus (e.g., EV68)	No alignment found*			No alignment found*		
Respiratory syncytial virus (RSV)	No alignment found*			No alignment found*		
Rhinovirus	No alignment found*			No alignment found*		
Chlamydia pneumoniae	No alignment found*			No alignment found*		
Mycobacterium tuberculosis	No alignment found*			No alignment found*		
Streptococcus pneumoniae	No alignment found*			No alignment found*		
Bordetella pertussis	No alignment found*			No alignment found*		
Pneumocystis jirovecii (PJP)	No alignment found*			No alignment found*		
Pseudomonas aeruginosa	No alignment found*			No alignment found*		

*The amplicon sequences were blasted against all the exclusive sequences with very low stringency cutoff (mapping length ≥ 60 bp; identity $\geq 50\%$; e-value ≤ 1). No alignment was found passing the cutoff and therefore no cross reactivity is expected.

Cross reactivity - Wet Laboratory Testing

Cross reactivity with SARS-CoV-1 Cross reactivity with SARS-CoV-1 was evaluated by testing inactivated SARS-CoV-1 whole virus. Gamma irradiated cultured SARS-CoV-1 (Urbani strain, lot number 58542036, BEI Resources, VA, USA) was diluted into pooled negative nasopharyngeal swabs in UTM-RT® at 1.0×10^5 PFU/mL. As shown in Table 13, SARS-CoV-1 did not interfere with the cobas® SARS-CoV-2 & Influenza A/B assay performance.

Table 13: SARS-CoV-2 cross reactivity with SARS-CoV-1

SARS-CoV-1 Concentration Tested	cobas® SARS-CoV-2 & Influenza A/B			
	SARS-CoV-2	Influenza A	Influenza B	IPC
	Result	Result	Result	Ct
1.00E+05 PFU/mL	Not Detected	Not Detected	Not Detected	31.6

Cross reactivity/Microbial Interference with other microorganisms

Cross reactivity with other non-SARS-CoV-2/Influenza microorganisms was evaluated against a panel comprising 24 microorganisms. Bacteria and *Candida albicans* were tested at $\geq 10^6$ units/mL. Viruses were tested at $\geq 10^5$ units/mL, or the highest available concentration. Pooled negative clinical nasopharyngeal swabs in UTM-RT® with or without presence of SARS-CoV-2, Influenza A/B at 3x LoD was used as sample matrices. No cross reactivity or microbial interference was observed for the microorganisms at the concentrations tested.

Table 14: Potentially cross-reactive organisms and concentrations tested

Potential Cross Reactive Organism	Testing Concentration*
Adenovirus	1.00E+05
Human Coronavirus 229E	1.00E+05
Human Coronavirus HKU1	1.00E+05
Human Coronavirus OC43	1.00E+05
Human Enterovirus D	1.00E+05
Human Metapneumovirus 27	1.00E+05
Human Rhinovirus B	1.00E+05
MERS-Coronavirus	1.00E+05
Parainfluenzavirus Type 1	1.00E+05
Parainfluenzavirus Type 2	1.00E+05
Parainfluenzavirus Type 3	1.00E+05
Parainfluenzavirus Type 4A	1.00E+05
Respiratory Syncytial Virus (Strain A2)	1.00E+05
Human Coronavirus NL63	2.55E+04
<i>Bordetella pertussis</i>	1.00E+06
<i>Candida albicans</i>	1.00E+06
<i>Haemophilus influenzae</i>	1.00E+06
<i>Legionella pneumophila</i>	1.00E+06
<i>Mycobacterium tuberculosis</i>	1.00E+06
<i>Mycoplasma pneumoniae</i>	1.00E+06
<i>Pseudomonas aeruginosa</i>	1.00E+06
<i>Staphylococcus epidermis</i>	1.00E+06
<i>Streptococcus pneumoniae</i>	1.00E+06
<i>Streptococcus pyogenes</i>	1.00E+06
<i>Streptococcus salivarius</i>	1.00E+06
<i>Chlamydia pneumonia</i>	7.90E+04
<i>Pneumocystis jirovecii</i>	5.00E+03

*EB/mL, CFU/mL, IU/mL, TCID50/mL, particles/mL, copies/mL, or PFU/mL

Co-infection (competitive inhibition)

Competitive inhibition for cobas® SARS-CoV-2 & Influenza A/B assay was evaluated by performing a series of dilution experiments with co-infected samples with one panel target at high concentration and one or more other targets at low concentrations. The purpose of these experiments was to identify concentrations at which the presence of the high concentration target would inhibit detection of the low concentration target(s) due to competition. Low concentrations were defined as ~3x LoD. High concentration targets were defined as either high (Ct 20-24) or very high (Ct 12-16) titers. Samples were tested in a series of dilutions until the low concentration targets were detected at 100% hit rate.

Inactivated SARS-CoV-2 (USA-WA1/2020), cultured influenza A (Brisbane/59/07), cultured influenza B (Florida/04/06 and Colorado/06/2017) were prepared in pooled negative nasopharyngeal swabs in UTM-RT® sample matrix. Three replicates were tested per condition. The concentrations tested in dilution experiments where competitive inhibition was no longer observed are presented in both ID₅₀/mL and copies/mL.

As cobas® SARS-CoV-2 & Influenza A/B detects nucleic acids, viral titers are also presented in copies/mL. The concentration of each viral stock in copies/mL was quantified using the RT-ddPCR (Reverse transcriptase droplet digital PCR) in a single target, single-plex assay with target specific PCR primers and probe sets designed to independently amplify influenza A, influenza B, or SARS-CoV-2 using the One-Step RT-ddPCR Advanced Kit for Probes (Bio Rad, cat # 1864021).

Summary of testing results are shown in the table below (Table 15). The concentrations of each high target shown below is where a 100% hit rate was achieved with low target concentrations at 3x LoD.

Table 15: Competitive inhibition – simulated co-infection study of influenza A, influenza B and SARS-CoV-2 targets

Virus Strain used for High Concentration Target	High Target Concentration Tested			Low Target Concentration (3x LoD) Detected with High Target Concentration Present					
				Influenza A		Influenza B		SARS-CoV-2	
	ID ₅₀ /mL	copies/mL	Mean Ct value	ID ₅₀ /mL	copies/mL	ID ₅₀ /mL	copies/mL	ID ₅₀ /mL	copies/mL
A/Brisbane/59/07	1.40E+04	8.34E+08	12	NT	NT	1.20E-02	4.85E+02	3.60E-02	3.60E+01
B/Florida/04/06	2.00E+01	8.09E+05	21	3.00E-03	1.79E+02	NT	NT	3.60E-02	3.60E+01
B/Colorado/06/2017	7.00E+03	8.54E+05	20	NT	NT	NT	NT	3.60E-02	3.60E+01
SARS-CoV-2 USA-WA1/2020	3.60E+01	3.65E+04	24	3.00E-03	1.79E+02	1.20E-02	4.85E+02	NT	NT

NT-not tested

Additional competitive inhibition testing was executed by setting the high target concentrations at levels observed in > 95% of positive clinical specimens for influenza B and SARS-CoV-2 targets. In the presence of these very high target concentrations, the detection of additional targets in the sample was achieved for SARS-CoV-2 at 4.50E-01 ID₅₀/mL, influenza A at 8.00E-01 ID₅₀/mL, and influenza B at 3.20E+00 ID₅₀/mL (Table 16).

Table 16: Competitive inhibition with very high target concentrations – Simulated co-infection study of influenza A, influenza B and SARS-CoV-2 targets

Virus Strain used for Very High Concentration Target	Very High Target Concentration Tested			Target Concentration Detected with Very High Target Concentration Present					
				Influenza A		Influenza B		SARS-CoV-2	
	ID ₅₀ /mL	copies/ mL	Mean Ct value	ID ₅₀ /mL	copies/ mL	ID ₅₀ /mL	copies/ mL	ID ₅₀ /mL	copies/mL
B/Florida/04/06	1.00E+03	4.04E+07	15	NT	NT	NT	NT	4.50E-01	4.56E+02
B/Colorado/06/2017	3.20E+05	3.94E+07	15	NT	NT	NT	NT	4.50E-01	4.56E+02
SARS-CoV-2 USA- WA1/2020	5.00E+03	5.07E+06	16	8.00E-01	4.77E+04	3.20E+00	1.29E+05	NT	NT

NT-not tested

Clinical performance evaluation – SARS-CoV-2

The clinical performance of **cobas**® SARS-CoV-2 & Influenza A/B test for the detection of SARS-CoV-2 was separately evaluated using retrospective and prospective clinical samples from individuals suspected of respiratory viral infection consistent with COVID-19.

Clinical performance evaluation using retrospective clinical specimens

The clinical performance of **cobas**® SARS-CoV-2 & Influenza A/B for the detection of SARS-CoV-2 was evaluated using 56 known SARS-CoV-2 positive remnant nasopharyngeal clinical samples and 231 negative clinical samples from prior to the COVID-19 pandemic (a mixture of nasopharyngeal and nasal swab samples) collected in UTM-RT® from patients with a suspected respiratory infection. Testing of clinical samples was performed with **cobas**® SARS-CoV-2 & Influenza A/B and an FDA-cleared EUA, **cobas**® SARS-CoV-2 for use on the **cobas**® 6800/8800 Systems.

As shown in Table 18, all 56 SARS-CoV-2 positive samples tested positive with both **cobas**® SARS-CoV-2 & Influenza A/B on **cobas**® Liat® System and **cobas**® SARS-CoV-2 on **cobas**® 6800/8800 Systems.

As shown in Table 17, 229 valid negative samples tested negative for SARS-CoV-2 with both **cobas**® SARS-CoV-2 & Influenza A/B on **cobas**® Liat® System and **cobas**® SARS-CoV-2 on **cobas**® 6800/8800 Systems. Five of the 231 negative clinical samples generated an initial invalid result with **cobas**® SARS-CoV-2 & Influenza A/B; 3 samples that generated valid results on repeat testing were included in the analysis and 2 samples that generated repeat invalid results were excluded from the analysis, yielding 229 valid negative samples. One negative sample tested positive for influenza A with **cobas**® SARS-CoV-2 & Influenza A/B; this result was confirmed with **cobas**® Influenza A/B & RSV on **cobas**® Liat® System (data not shown).

For retrospective specimens, the results of the clinical performance evaluation demonstrated 100% positive percent agreement and 100% negative percent agreement as compared to **cobas**® SARS-CoV-2 on **cobas**® 6800/8800 Systems.

Table 17: Clinical performance comparison with **cobas**® SARS-CoV-2 on **cobas**® 6800/8800 Systems – Retrospective specimens

		cobas ® SARS-CoV-2 on cobas ® 6800/8800 Systems	
		Positive	Negative
cobas ® SARS-CoV-2 & Influenza A/B on cobas ® Liat® System	Positive	56	0
	Negative	0	229*

* 2 repeated invalid samples were not included in the analysis

PPA 100% (95% CI: 93.6% - 100%)
NPA 100% (95% CI: 98.4% - 100%)

Clinical performance evaluation using prospective clinical samples

The clinical performance of **cobas**® SARS-CoV-2 & Influenza A/B test for the detection of SARS-CoV-2 was evaluated using paired clinical nasopharyngeal swab (NPS) and nasal swab (NS) samples prospectively collected in UTM from patients with a suspected respiratory infection. Testing of prospective clinical samples was performed with **cobas**® SARS-CoV-2 & Influenza A/B test and a composite reference method consisting of three highly sensitive comparator FDA-cleared EUA RT-PCR tests. The composite reference SARS-CoV-2 result was determined by consensus between two comparator tests, and a third comparator test was used to adjudicate the composite reference SARS-CoV-2 result in cases of discrepancy.

No coinfections with SARS-CoV-2 and influenza A/B were detected. No specimens tested in this performance evaluation were influenza A or influenza B positive by **cobas**® SARS-CoV-2 & Influenza A/B test.

Among the total 935 NPS specimens determined to be evaluable, 7 were excluded due to invalid results from either **cobas**® SARS-CoV-2 & Influenza A/B test or comparator tests. As such, 928 valid samples were tested with both **cobas**® SARS-CoV-2 & Influenza A/B test and the composite reference method, and these were included in the performance analysis.

As shown in Table 17 for prospective NPS specimens, **cobas**® SARS-CoV-2 & Influenza A/B test demonstrated 96.3% positive percent agreement and 99.6% negative percent agreement compared to the composite reference method for SARS-CoV-2 detection. Three negative NPS samples tested positive for SARS-CoV-2 with **cobas**® SARS-CoV-2 & Influenza A/B test; these samples showed late Ct values, which are indicative of samples from individuals with viral loads near or below the limit of detection of both **cobas**® SARS-CoV-2 & Influenza A/B test and the comparator tests.

Table 18: Clinical performance comparison with the composite reference method – Prospective NPS specimens

		Composite Reference Method SARS-CoV-2 Result	
		Positive	Negative
cobas ® SARS-CoV-2 & Influenza A/B on cobas ® Liat® System	Positive	77	3
	Negative	3	845

PPA 96.3% (95% CI: 89.5% - 98.7%)

NPA 99.6% (95% CI: 99.0% - 99.9%)

Among the total 937 NS specimens determined to be evaluable, 10 samples were excluded due to invalid results from either **cobas**® SARS-CoV-2 & Influenza A/B test or comparator tests. As such, 927 valid samples were tested with both **cobas**® SARS-CoV-2 & Influenza A/B test and the composite reference method, and these were included in the performance analysis: 452 (48.8%) were healthcare provider-collected and 475 (51.2%) were self-collected nasal swabs.

As shown in Table 18 for prospective NS specimens, **cobas**® SARS-CoV-2 & Influenza A/B test demonstrated 100% positive percent agreement and 99.6% negative percent agreement compared to the composite reference method for SARS-CoV-2 detection. Three negative NS samples tested positive for SARS-CoV-2 with **cobas**® SARS-CoV-2 & Influenza A/B test; these

samples showed late Ct values, which are indicative of samples from individuals with viral loads near or below the limit of detection of both cobas® SARS-CoV-2 & Influenza A/B test and the comparator tests.

Table 19: Clinical performance comparison with the composite reference method – Prospective NS specimens

		Composite Reference Method SARS-CoV-2 Result	
		Positive	Negative
cobas® SARS-CoV-2 & Influenza A/B on cobas® Liat® System	Positive	75	3
	Negative	0	849

PPA 100% (95% CI: 95.1% - 100%)

NPA 99.6% (95% CI: 99.0% - 99.9%)

Non-clinical performance - Influenza A/B

Analytical sensitivity

The Limit of Detection (LoD) was evaluated using 3 strains of influenza A and 2 strains of influenza B. The LoD was determined by limiting dilution studies using these titrated viruses. The viruses were spiked into negative nasopharyngeal swab (NPS) in UTM-RT® sample matrix. The LoD was determined to be 2×10^{-3} - 2×10^{-2} TCID₅₀/mL for influenza A strains, and 2×10^{-3} - 4×10^{-3} TCID₅₀/mL for Influenza B strains (Table 20).

Table 20: LoD determination for influenza A and influenza B strains

Virus Strain	LoD (TCID ₅₀ /mL)
A/Brisbane/10/07	2.0×10^{-2}
A/Brisbane/59/07	2.0×10^{-3}
A/NY/01/2009	2.0×10^{-2}
B/Florida/04/06	2.0×10^{-3}
B/Malaysia/2506/04	4.0×10^{-3}

Note: Analytical sensitivity of cobas® SARS-CoV-2 & Influenza A/B was evaluated and shown to be equivalent to cobas® Influenza A/B & RSV using cultured A/Brisbane/59/07 and B/Florida/04/06 (data not shown).

Reproducibility

Reproducibility study assesses the total variability of the assay in detecting influenza A/B across operators, study sites, testing days, Analyzers, and assay tube lots. The reproducibility was evaluated at 3 sites. Two operators at each of the 3 sites tested a 10-member reproducibility panel in triplicate on 5 different days, for a total of ~900 runs (10 panel members x 3 replicates x 2 operators x 5 days x 3 sites). Nine Analyzers and 3 assay tube lots were used. The reproducibility panel comprises a high negative, a low positive, and a moderate positive for each of influenza A and influenza B, in addition to a negative sample. For a given virus, the expected result for the true negative and the high negative panel member is “Not Detected,” while the expected result for the low positive and moderate positive panel member is “Detected.” Percent agreement with expected result, mean Ct, and Ct %CV for each site are shown in Table 21 and Table 22.

Table 21: Influenza A reproducibility

	Site 1			Site 2			Site 3			Total	
Sample	Agreement w/ expected result	Avg Ct	Ct %CV	Agreement w/ expected result	Ct Avg	Ct %CV	Agreement w/ expected result	Ct Avg	Ct %CV	Agreement w/ expected result	95% CI
Negative	30 / 30	-	-	31 / 31	-	-	30 / 30	-	-	91 / 91 (100.0%)	96.0% - 100.0%
Flu A High Negative*	29 / 30	37.0	-	30 / 30	-	-	29 / 30	35.7	-	88 / 90 (97.8%)	92.3% - 99.4%
Flu A Low Positive*	30 / 30	32.7	2.9%	30 / 30	32.1	1.6%	30 / 30	32.3	1.6%	90 / 90 (100.0%)	95.9% - 100.0%
Flu A Moderate Positive*	30 / 30	30.4	1.0%	30 / 30	30.0	1.2%	30 / 30	30.1	0.9%	90 / 90 (100.0%)	95.9% - 100.0%
Flu B High Negative*	30 / 30	-	-	31 / 31	-	-	30 / 30	-	-	91 / 91 (100.0%)	96.0% - 100.0%
Flu B Low Positive*	30 / 30	-	-	30 / 30	-	-	29 / 29†	-	-	89 / 89 (100.0%)	95.9% - 100.0%
Flu B Moderate Positive*	30 / 30	-	-	30 / 30	-	-	30 / 30	-	-	90 / 90 (100.0%)	95.9% - 100.0%
Total Agreement	209 / 210 (99.5%)			212 / 212 (100.0%)			208 / 209 (99.5%)			629 / 631 (99.7%)	98.9% - 100.0%

† One of 30 influenza B Low Positive replicates yielded an “Assay Invalid. Repeat Assay” result, and was not repeated.

*Guidance for Industry and FDA Staff Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Influenza Viruses. Document issued on: July 15, 2011

Table 22: Influenza B reproducibility

	Site 1			Site 2			Site 3			Total	
Sample	Agreement w/ expected result	Ct Avg	Ct %CV	Agreement w/ expected result	Ct Avg	Ct %CV	Agreement w/ expected result	Ct Avg	Ct %CV	Agreement w/ expected result	95% CI
Negative	30 / 30	-	-	31 / 31	-	-	30 / 30	-	-	91 / 91 (100.0%)	96.0% - 100.0%
Flu A High Negative*	30 / 30	-	-	30 / 30	-	-	30 / 30	-	-	90 / 90 (100.0%)	95.9% - 100.0%
Flu A Low Positive*	30 / 30	-	-	30 / 30	-	-	30 / 30	-	-	90 / 90 (100.0%)	95.9% - 100.0%
Flu A Moderate Positive*	30 / 30	-	-	30 / 30	-	-	30 / 30	-	-	90 / 90 (100.0%)	95.9% - 100.0%
Flu B High Negative*	29 / 30	35.1	-	31 / 31	-	-	30 / 30	-	-	90 / 91 (98.9%)	94.0% - 99.8%
Flu B Low Positive*	30 / 30	31.9	1.8%	30 / 30	31.6	1.4%	29 / 29 [†]	31.6	1.5%	89 / 89 (100.0%)	95.9% - 100.0%
Flu B Moderate Positive*	30 / 30	30.8	1.3%	30 / 30	30.4	1.4%	30 / 30	30.5	1.3%	90 / 90 (100.0%)	95.9% - 100.0%
Total Agreement	209 / 210 (99.5%)			212 / 212 (100.0%)			208 / 209 (99.5%)			629 / 631 (99.7%)	98.9% - 100.0%

[†] One of 30 influenza B Low Positive replicates yielded an “Assay Invalid. Repeat Assay” result, and analysis was not repeated.

*Guidance for Industry and FDA Staff Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Influenza Viruses. Document issued on: July 15, 2011

Reactivity/inclusivity

The reactivity study evaluates the ability to detect influenza strains representing temporal and geographical diversity. The reactivity/inclusivity was evaluated with 28 influenza A and 15 influenza B strains. Influenza A strains included 14 influenza A/H1 strains (including 3 H1N1 pdm09 strains), 12 influenza A/H3 strains (including 1 H3N2v strain), 1 influenza A/H7N9 strain, and 1 influenza A/H5N1 reassortant strain. Influenza B strains included that from both the Victoria lineage and Yamagata lineage. All strains were detected at the concentrations tested (Table 23).

Table 23: Results of testing influenza A and influenza B strains

Virus Strain	Type / Subtype	Test Concentration	Inf A Result	Inf B Result
A/Aichi/2/68	Influenza A/H3N2	1.0×10^2 CEID ₅₀ /mL	+	–
A/Alice	Influenza A/H3N2	5.0×10^1 CEID ₅₀ /mL	+	–
A/Anhui/1/2013	Influenza A/H7N9 (Eurasian lineage)	1.0×10^3 TCID ₅₀ /mL	+	–
A/Brisbane/10/07	Influenza A/H3N2	2.0×10^{-2} TCID ₅₀ /mL	+	–
A/Brisbane/59/07	Influenza A/H1N1	2.0×10^{-3} TCID ₅₀ /mL	+	–
A/Cambodia/X0810301/2013(H5N1)-PR8-IDCDC-RG34B	Influenza A/H5N1 reassortant	2.5×10^1 CEID ₅₀ /mL	+	–
A/Denver/1/57	Influenza A/H1N1	1.0×10^2 CEID ₅₀ /mL	+	–
A/FM/1/47	Influenza A/H1N1	1.0×10^2 CEID ₅₀ /mL	+	–
A/H3/Perth/16/09	Influenza A/H3N2	2.5×10^{-1} TCID ₅₀ /mL	+	–
A/Hong Kong/8/68	Influenza A/H3N2	1.0×10^2 TCID ₅₀ /mL	+	–
A/Indiana/8/2011	Influenza A/H3N2v	5.0×10^{-1} TCID ₅₀ /mL	+	–
A/Mal/302/54	Influenza A/H1N1	4.0×10^2 CEID ₅₀ /mL	+	–
A/MRC2	Influenza A/H3	1.0×10^2 CEID ₅₀ /mL	+	–
A/New Caledonia/20/99	Influenza A/H1N1	1.0×10^2 TCID ₅₀ /mL	+	–
A/New Jersey/8/76	Influenza A/H1N1	1.0×10^1 CEID ₅₀ /mL	+	–
A/NY/01/2009	Influenza A/H1N1 pdm09	2.0×10^{-2} TCID ₅₀ /mL	+	–
A/NY/02/2009	Influenza A/H1N1 pdm09	2.5×10^{-2} TCID ₅₀ /mL	+	–
A/NY/03/2009	Influenza A/H1N1 pdm09	2.0×10^{-1} TCID ₅₀ /mL	+	–
A/Port Chalmers/1/73	Influenza A/H3N2	1.0×10^2 CEID ₅₀ /mL	+	–
A/PR/8/34	Influenza A/H1N1	5.0×10^0 TCID ₅₀ /mL	+	–
A/Solomon Island/3/2006	Influenza A/H1N1	5.0×10^{-2} TCID ₅₀ /mL	+	–
A/Swine/1976/31	Influenza A/H1N1	1.0×10^1 CEID ₅₀ /mL	+	–
A/Swine/Iowa/15/30	Influenza A/H1N1	1.0×10^2 CEID ₅₀ /mL	+	–
A/Texas/50/2012	Influenza A/H3N2	1.0×10^{-1} TCID ₅₀ /mL	+	–
A/Victoria/3/75	Influenza A/H3N2	1.0×10^2 CEID ₅₀ /mL	+	–
A/Victoria/361/2011	Influenza A/H3N2	2.0×10^{-2} TCID ₅₀ /mL	+	–
A/Weiss/43	Influenza A/H1N1	1.0×10^3 TCID ₅₀ /mL	+	–
A/Wisconsin/67/05	Influenza A/H3N2	5.0×10^{-1} TCID ₅₀ /mL	+	–
B/Allen/45	Influenza B	5.0×10^{-1} TCID ₅₀ /mL	–	+
B/Brisbane/60/2008	Influenza B (Victoria lineage)	1.0×10^{-2} TCID ₅₀ /mL	–	+
B/Florida/04/06	Influenza B (Yamagata lineage)	2.0×10^{-3} TCID ₅₀ /mL	–	+
B/Florida/07/04	Influenza B (Yamagata lineage)	5.0×10^{-2} TCID ₅₀ /mL	–	+
B/GL/1739/54	Influenza B	2.0×10^0 TCID ₅₀ /mL	–	+
B/HongKong/5/72	Influenza B	2.5×10^{-1} TCID ₅₀ /mL	–	+
B/Lee/40	Influenza B	2.5×10^{-1} TCID ₅₀ /mL	–	+
B/Malaysia/2506/04	Influenza B (Victoria lineage)	4.0×10^{-3} TCID ₅₀ /mL	–	+
B/Maryland/1/59	Influenza B	2.0×10^{-2} TCID ₅₀ /mL	–	+
B/Mass/3/66	Influenza B	1.0×10^1 TCID ₅₀ /mL	–	+
B/Massachusetts/2/2012	Influenza B (Yamagata lineage)	5.0×10^{-3} TCID ₅₀ /mL	–	+
B/Nevada/03/2011	Influenza B (Victoria lineage)	2.5×10^{-1} CEID ₅₀ /mL	–	+
B/Taiwan/2/62	Influenza B	2.0×10^{-1} TCID ₅₀ /mL	–	+
B/Texas/6/2011	Influenza B (Yamagata lineage)	1.0×10^{-1} TCID ₅₀ /mL	–	+
B/Wisconsin/1/2010	Influenza B (Yamagata lineage)	5.0×10^{-1} TCID ₅₀ /mL	–	+

Cross reactivity

Cross-reactivity study evaluates potential cross reactivity with non-influenza microorganisms that may be present in nasopharyngeal swab samples. The cross reactivity was evaluated against a panel comprising human genomic DNA and 35 microorganisms. Bacteria and *Candida albicans* were tested at $\geq 10^6$ CFU/mL. Viruses were tested at $\geq 10^5$ TCID₅₀/mL, or the highest available concentration. No cross reactivity was observed for the human genomic DNA or the microorganisms at the concentrations tested (Table 24).

Table 24: Influenza A/B cross-reactivity testing results

Microorganism	Test Concentration	Inf A Result	Inf B Result
Adenovirus Type 1	9.0×10^5 TCID ₅₀ /mL	–	–
Adenovirus Type 7	1.4×10^5 TCID ₅₀ /mL	–	–
Cytomegalovirus	4.5×10^4 TCID ₅₀ /mL	–	–
Epstein Barr Virus	2.5×10^5 TCID ₅₀ /mL	–	–
Herpes Simplex Virus	1.4×10^5 TCID ₅₀ /mL	–	–
Human Coronavirus 229E	8.0×10^3 TCID ₅₀ /mL	–	–
Human Coronavirus OC43	8.0×10^4 TCID ₅₀ /mL	–	–
Human Enterovirus 68	1.0×10^5 TCID ₅₀ /mL	–	–
Human Metapneumovirus	7.0×10^3 TCID ₅₀ /mL	–	–
Human Parainfluenza Type 1	3.7×10^5 TCID ₅₀ /mL	–	–
Human Parainfluenza Type 2	7.5×10^5 TCID ₅₀ /mL	–	–
Human Parainfluenza Type 3	4.5×10^5 TCID ₅₀ /mL	–	–
Human Rhinovirus Type 1A	8.0×10^5 TCID ₅₀ /mL	–	–
Measles	8.0×10^4 TCID ₅₀ /mL	–	–
Mumps Virus	8.0×10^4 TCID ₅₀ /mL	–	–
Varicella-Zoster Virus	4.4×10^3 TCID ₅₀ /mL	–	–
<i>Bordetella pertussis</i>	2.2×10^6 CFU/mL	–	–
<i>Candida albicans</i>	4.2×10^6 CFU/mL	–	–
<i>Chlamydia pneumoniae</i>	8.0×10^4 TCID ₅₀ /mL	–	–
<i>Corynebacterium sp</i>	3.6×10^6 CFU/mL	–	–
<i>Escherichia coli</i>	1.9×10^6 CFU/mL	–	–
<i>Haemophilus influenzae</i>	2.3×10^6 CFU/mL	–	–
<i>Lactobacillus sp</i>	1.9×10^6 CFU/mL	–	–
<i>Legionella pneumophila</i>	6.7×10^6 CFU/mL	–	–
<i>Moraxella catarrhalis</i>	2.5×10^6 CFU/mL	–	–
<i>Mycobacterium tuberculosis</i>	2.8×10^6 copies/mL [†]	–	–
<i>Mycoplasma pneumoniae</i>	2.9×10^6 copies/mL [†]	–	–
<i>Neisseria elongate</i>	2.0×10^6 CFU/mL	–	–
<i>Neisseria meningitidis</i>	2.2×10^6 CFU/mL	–	–
<i>Pseudomonas aeruginosa</i>	2.3×10^6 CFU/mL	–	–
<i>Staphylococcus aureus</i>	2.4×10^6 CFU/mL	–	–
<i>Staphylococcus epidermidis</i>	1.9×10^6 CFU/mL	–	–
<i>Streptococcus pneumoniae</i>	1.8×10^6 CFU/mL	–	–
<i>Streptococcus pyogenes</i>	2.5×10^6 CFU/mL	–	–
<i>Streptococcus salivarius</i>	4.3×10^6 CFU/mL	–	–
Human genomic DNA	1.0×10^4 copies/mL	–	–

[†] Testing was performed with genomic DNA due to difficulties in propagation of these bacteria.

Interfering microorganisms

Interfering microorganism study evaluates whether non-influenza microorganisms that may be present in nasopharyngeal swab samples can interfere in the detection of influenza A or influenza B. The panel comprising human genomic DNA and 35 microorganisms tested in the cross-reactivity study was tested for potential interference. Bacteria and *Candida albicans* were tested at $\geq 10^6$ CFU/mL and viruses were tested at $\geq 10^5$ TCID₅₀/mL or the highest available concentration, in the presence of 1 influenza A strain and 1 influenza B strain at $\sim 3\times$ LoD concentration in negative NPS in UTM-RT® matrix. Results show that the presence of human genomic DNA or the microorganisms at the concentrations tested did not interfere with the detection of influenza A or influenza B (Table 25).

Table 25: Influenza A/B interfering microorganisms study results

Microorganism	Test Concentration	1 Influenza A & 1 Influenza B strain at $\sim 3\times$ LoD	
		Inf A Result	Inf B Result
Adenovirus Type 1	9.0×10^5 TCID ₅₀ /mL	+	+
Adenovirus Type 7	1.4×10^5 TCID ₅₀ /mL	+	+
Cytomegalovirus	4.5×10^4 TCID ₅₀ /mL	+	+
Epstein Barr Virus	2.5×10^5 TCID ₅₀ /mL	+	+
Herpes Simplex Virus	1.4×10^5 TCID ₅₀ /mL	+	+
Human Coronavirus 229E	8.0×10^3 TCID ₅₀ /mL	+	+
Human Coronavirus OC43	8.0×10^4 TCID ₅₀ /mL	+	+
Human Enterovirus 68	1.0×10^5 TCID ₅₀ /mL	+	+
Human Metapneumovirus	7.0×10^3 TCID ₅₀ /mL	+	+
Human Parainfluenza Type 1	3.7×10^5 TCID ₅₀ /mL	+	+
Human Parainfluenza Type 2	7.5×10^5 TCID ₅₀ /mL	+	+
Human Parainfluenza Type 3	4.5×10^5 TCID ₅₀ /mL	+	+
Human Rhinovirus Type 1A	8.0×10^5 TCID ₅₀ /mL	+	+
Measles	8.0×10^4 TCID ₅₀ /mL	+	+
Mumps Virus	8.0×10^4 TCID ₅₀ /mL	+	+
Varicella-Zoster Virus	4.4×10^3 TCID ₅₀ /mL	+	+
<i>Bordetella pertussis</i>	2.2×10^6 CFU/mL	+	+
<i>Candida albicans</i>	4.2×10^6 CFU/mL	+	+
<i>Chlamydia pneumoniae</i>	8.0×10^4 TCID ₅₀ /mL	+	+
<i>Corynebacterium sp</i>	3.6×10^6 CFU/mL	+	+
<i>Escherichia coli</i>	1.9×10^6 CFU/mL	+	+
<i>Haemophilus influenzae</i>	2.3×10^6 CFU/mL	+	+
<i>Lactobacillus sp</i>	1.9×10^6 CFU/mL	+	+
<i>Legionella pneumophila</i>	6.7×10^6 CFU/mL	+	+
<i>Moraxella catarrhalis</i>	2.5×10^6 CFU/mL	+	+
<i>Mycobacterium tuberculosis</i>	2.8×10^6 copies/mL [†]	+	+
<i>Mycoplasma pneumoniae</i>	2.9×10^6 copies/mL [†]	+	+
<i>Neisseria elongata</i>	2.0×10^6 CFU/mL	+	+
<i>Neisseria meningitidis</i>	2.2×10^6 CFU/mL	+	+
<i>Pseudomonas aeruginosa</i>	2.3×10^6 CFU/mL	+	+
<i>Staphylococcus aureus</i>	2.4×10^6 CFU/mL	+	+
<i>Staphylococcus epidermidis</i>	1.9×10^6 CFU/mL	+	+
<i>Streptococcus pneumoniae</i>	1.8×10^6 CFU/mL	+	+
<i>Streptococcus pyogenes</i>	2.5×10^6 CFU/mL	+	+
<i>Streptococcus salivarius</i>	4.3×10^6 CFU/mL	+	+
Human Genomic DNA	1.0×10^4 copies/mL	+	+

[†] Testing was performed with genomic DNA due to difficulties in propagation of these bacteria

Interfering substances

Potentially interfering substances that may be encountered in respiratory specimens were evaluated. Medically and/or physiologically relevant concentrations of potential interferents were tested with 2 influenza A strains and 2 influenza B strains at ~3x LoD. As shown in Table 26, substances at the concentrations tested did not interfere in the detection of influenza A and influenza B.

Table 26: Influenza A/B interfering substances study results

Potential Interferent	Active Ingredient	Concentration
Mucin: bovine submaxillary gland, type I-S	Purified mucin protein	5 mg/mL
Blood	-	5% (v/v)
Nasal spray – Afrin	Oxymetazoline	5% (v/v)
Nasal corticosteroids – Veramyst	Fluticasone	5% (v/v)
Nasal gel – Zicam	Galphimia glauca, Histaminum hydrochloricum, Luffa operculata, Sulphur	5% (v/v)
Throat lozenges, oral anesthetic and analgesic – Cepacol	Benzocaine, Menthol	5 mg/mL
Antibiotic, nasal ointment – Bactroban	Mupirocin	5 mg/mL
Antiviral drug – Relenza	Zanamivir	5 mg/mL
Antiviral drug – Tamiflu	Oseltamivir	7.5 mg/mL
Antimicrobial, systemic	Tobramycin	4 µg/mL

Clinical studies - Influenza A/B

The clinical performance of the assay was evaluated at 12 CLIA waived healthcare facilities. Prospective nasopharyngeal swab (NPS) specimens were collected from patients with signs and symptoms of respiratory infection in the US during the 2013-2014 and 2014-2015 flu seasons, and were tested prospectively at the study sites. Additionally, retrospective NPS specimens were obtained from 2 reference laboratories and were distributed to and tested at 3 of the 12 sites. The retrospective specimens were worked into the daily workload of those sites for testing.

Each patient's specimen was tested for influenza A/B and an FDA-cleared laboratory-based multiplexed real-time reverse transcriptase PCR (RT-PCR) test (comparator test). The results for influenza A/B were compared against the results from the comparator test. A total of 1,350 prospective NPS specimens and 292 retrospective NPS specimens were included in the performance analysis.

For prospective specimens, a total of 1,421 subjects were enrolled in this study. Of these, 41 specimens did not meet eligibility criteria. Additionally, 17 and 13 specimens were excluded due to invalid results from the Analyzer and the comparator tests, respectively. As such, a total of 1,350 prospective nasopharyngeal swab (NPS) specimens were included in the performance analysis (Table 27 and Table 28). Compared to the comparator test, the assay demonstrated positive agreement of 98.3% and 95.2% for influenza A and influenza B, respectively; and negative agreement of 96.0% and 99.4% for influenza A and influenza B, respectively.

Table 27: Clinical performance with prospective NPS specimens – influenza A

		Comparator Test		
		Positive	Negative	Total
Liat	Positive	172	47 ^a	219
	Negative	3	1128	1131
	Total	175	1175	1350

	%	95% CI
Positive Agreement	98.3%	(95.1% – 99.4%)
Negative Agreement	96.0%	(94.7% – 97.0%)

^a Forty-one cobas® Influenza A/B & RSV positive, lab-based RT-PCR negative specimens were tested by PCR/sequencing. Of these, 18 were positive and 23 were negative by PCR/sequencing.

Table 28: Clinical performance with prospective NPS specimens – influenza B

		Comparator Test		
		Positive	Negative	Total
Liat	Positive	40	8 ^a	48
	Negative	2	1300	1302
	Total	42	1308	1350

	%	95% CI
Positive Agreement	95.2%	(84.2% – 98.7%)
Negative Agreement	99.4%	(98.8% – 99.7%)

^a Six cobas® Influenza A/B & RSV positive, lab-based RT-PCR negative specimens were tested by PCR/sequencing. Of these, 5 were positive and 1 was negative by PCR/sequencing.

For retrospective specimens, a total of 300 specimens were tested at clinical sites. Of these, 5 and 3 specimens were excluded due to invalid results from the System and the comparator tests, respectively. As such, a total of 292 retrospective nasopharyngeal swab (NPS) specimens were included in the performance analysis (Table 29 and Table 30). Compared to the comparator test, Inf A and Inf B demonstrated positive agreement of 98.7% and 99.0% , respectively; and negative agreement of 99.1% and 99.5% for Inf A and Inf B, respectively.

Table 29: Clinical performance with retrospective NPS specimens – influenza A

		Comparator Test		
		Positive	Negative	Total
Liat	Positive	76	2 ^a	78
	Negative	1	213	214
	Total	77	215	292

	%	95% CI
Positive Agreement	98.7%	(93.0% - 99.8%)
Negative Agreement	99.1%	(96.7% - 99.7%)

^a One **cobas**® Influenza A/B & RSV positive, lab-based RT-PCR negative specimen was tested by PCR/sequencing. This sample was negative by PCR/sequencing.

Table 30: Clinical performance with retrospective NPS specimens – influenza B

		Comparator Test		
		Positive	Negative	Total
Liat	Positive	97	1	98
	Negative	1	193	194
	Total	98	194	292

	%	95% CI
Positive Agreement	99.0%	(94.4% - 99.8%)
Negative Agreement	99.5%	(97.1% - 99.9%)

During the clinical study testing of prospective and retrospective specimens, the assay initial invalid rate was 1.8% (29/1,656 specimens, 95% CI: 1.2% - 2.5%). Of these 29 specimens with initial invalid results, 5 specimens had 2 invalid or aborted runs, 16 specimens had 1 invalid run and were not repeated due to unavailability of residual samples, and 8 specimens had an initial invalid run and a repeat test per product instructions for use yielded a valid result.

Following addition of the SARS-CoV-2 assay targets, a study using banked retrospective clinical samples was conducted to demonstrate that the sensitivity and inclusivity of the existing influenza A and B targets was not altered. For this study, 11 nasopharyngeal swab specimens from patients with confirmed influenza A (n = 5) or influenza B (n = 6) infection were tested in parallel with both **cobas**® SARS-CoV-2 & Influenza A/B and **cobas**® Influenza A/B & RSV. The CDC 2019 Human Influenza Virus Panel, including two additional influenza A (H1N1 strain Brisbane/02/2018 and H3N2 strain Perth/16/2009) and two influenza B (Victoria lineage Colorado/06/2017 and Yamagata lineage Phuket/3073/2013) strains, were also tested in this study. Ct ranges of the sample included in the study ranged from 17.3 to 36.0. Agreement of both test scripts with expected results as 100% (15/15).

Failure codes

The result report may contain failure codes as described in Table 31e, depending on potential run failures. For any questions, please contact your Roche Service representative.

Table 31: Failure codes and definitions

Failure Code Summary			
Failure Codes	Sample	Negative Control	Positive Control
g0*	IPC out of range. Repeat run.	IPC out of range. Repeat run.	IPC out of range. Repeat run.
g1			
g2			
g3			
g4			
x4	One or more targets out of range. Repeat run.	N/A	N/A
FP	N/A	One or more targets out of range. Repeat run.	N/A
b1	N/A	N/A	Target out of range. Repeat run.
b2			
b4			
a1	N/A	N/A	Target out of range. Repeat run.
a2			
a4			
r1	N/A	N/A	Target out of range. Repeat run.
r2			
r3			
r4			

Note: * Failure code g0 does not appear for Positive Control

Additional information

Key test features

Sample type

Nasopharyngeal and Nasal swab samples collected in the Copan UTM-RT® System or the BD™ UVT System or Thermo Fischer™ Remel (M4®, M4RT®, M5®, M6®), and 0.9% physiological saline.

Minimum amount of sample required

Approximately 0.2 mL





























Test duration

Results are available within approximately 20 minutes after loading the sample on the instrument.

Symbols

The following symbols are used in labeling for Roche PCR diagnostic products.

Table 32: Symbols used in labeling for Roche PCR diagnostics products

 Age/DOB	Age or Date of Birth	 Date of manufacture	Date of manufacture
 Ancillary Software	Ancillary Software	 Distributed by	Distributed by
 Assigned Range [copies/mL]	Assigned Range (copies/mL)	 Do not re-use	Do not re-use
 Assigned Range [IU/mL]	Assigned Range (IU/mL)	 Female	Female
 EC REP	Authorized representative in the European Community	 For IVD performance evaluation only	For IVD performance evaluation only
 Barcode Data Sheet	Barcode Data Sheet	 GTIN	Global Trade Item Number
 LOT	Batch code	 IVD	<i>In vitro</i> diagnostic medical device
 Biological risks	Biological risks	 LLR	Lower Limit of Assigned Range
 REF	Catalogue number	 Male	Male
 Collect Date	Collect date	 Manufacturer	Manufacturer
 Consult instructions for use	Consult instructions for use	 Negative control	Negative control
 Contains sufficient for <n> tests	Contains sufficient for <n> tests	 Non sterile	Non sterile
 Contents of kit	Contents of kit	 Patient number	Patient number
 Control	Control	 Patient Name	Patient Name



Peel here




Positive control



This way up



Unique Device Identification




QS copies per PCR reaction, use the QS copies per PCR reaction in calculation of the results.



Ultrasensitive Procedure



Upper Limit of Assigned Range



QS IU per PCR reaction, use the QS International Units (IU) per PCR reaction in calculation of the results.



Urine Fill Line



Serial number

Rx Only

US Only: Federal law restricts this device to sale by or on the order of a physician.



Site



Use-by date



Standard Procedure



Device for near-patient testing



Sterilized using ethylene oxide



Device Not for Near Patient Testing



Store in the dark



Device for self-testing



Temperature limit



Device not for self-testing



Test Definition File



CE marking of conformity; this device is in conformity with the applicable requirements for CE marking of an *in vitro* diagnostic medical device

Technical support

For technical support (assistance) please reach out to your local affiliate:
https://www.roche.com/about/business/roche_worldwide.htm

Manufacturer and distributors

Table 33: Manufacturer and distributors



Roche Molecular Systems, Inc.
 1080 US Highway 202 South
 Branchburg, NJ 08876 USA
www.roche.com



Roche Diagnostics GmbH
 Sandhofer Strasse 116
 68305 Mannheim, Germany

Roche Diagnostics
 9115 Hague Road
 Indianapolis, IN 46250-0457 USA
 (For Technical Assistance call the
 Roche Response Center
 toll-free: 1-800-800-5973)

Trademarks and patents

See <http://www.roche-diagnostics.us/patents>

Copyright

©2020 Roche Molecular Systems, Inc.



Roche Diagnostics GmbH
 Sandhofer Str. 116
 68305 Mannheim
 Germany



References

1. Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*. 2020;581:465-9. PMID: 32235945.
2. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395:507-13. PMID: 32007143.
3. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020;382:727-33. PMID: 31978945.
4. World Health Organization. WHO Director General's opening remarks at the media briefing on COVID-19 - 11 March, 2020. <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>.
5. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) Situation Summary. Updated April 19, 2020. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/summary.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fsummary.html.
6. Faust JS, Del Rio C. Assessment of Deaths From COVID-19 and From Seasonal Influenza. *JAMA Intern Med*. 2020. PMID: 32407441.
7. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment. *N Engl J Med*. 2020;382:692-4. PMID: 31978293.
8. Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients coinfecting with 2019 novel coronavirus and influenza virus in Wuhan, China. *J Med Virol*. 2020. PMID: 32196707.
9. Liang WH, Guan WJ, Li CC, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. *Eur Respir J*. 2020;55. PMID: 32269086.
10. Basile K, Kok J, Dwyer DE. Point-of-care diagnostics for respiratory viral infections. *Expert Rev Mol Diagn*. 2018;18:75-83. PMID: 29251007.
11. Uyeki TM. Influenza. *Ann Intern Med*. 2017;167:ITC33-ITC48. PMID: 28869984.
12. Caliendo AM, Gilbert DN, Ginocchio CC, et al. Better tests, better care: improved diagnostics for infectious diseases. *Clin Infect Dis*. 2013;57 Suppl 3:S139-70. PMID: 24200831.
13. Center for Disease Control and Prevention. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institutes of Health HHS Publication No. (CDC) 21-1112, revised December 2009.
14. Clinical and Laboratory Standards Institute (CLSI). Protection of laboratory workers from occupationally acquired infections. Approved Guideline-Fourth Edition. CLSI Document M29-A4:Wayne, PA;CLSI, 2014.
15. Centers for Disease Control and Prevention. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19). Updated May 5, 2020. <https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html>.

16. Centers for Disease Control and Prevention. Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19). Updated on May 11, 2020. <https://www.cdc.gov/coronavirus/2019-nCoV/lab/lab-biosafety-guidelines.html>.
17. World Health Organization. Laboratory biosafety guidance related to coronavirus disease (COVID-19): Interim Guidance. May 13, 2020. [https://www.who.int/publications/i/item/laboratory-biosafety-guidance-related-to-coronavirus-disease-\(covid-19\)](https://www.who.int/publications/i/item/laboratory-biosafety-guidance-related-to-coronavirus-disease-(covid-19)).

Document revision

Document Revision Information	
Doc Rev. 1.0 09/2020	First Publishing.
Doc Rev. 2.0 09/2020	<p>Updated Intended use for minor wording changes</p> <p>Updated to include 0.9% physiological saline solution as an additional media type</p> <p>Updated to include new Copan UTM-RT® and Thermo Fisher™ Scientific Remel™ part numbers acceptable for use with this test</p> <p>Please contact your local Roche Representative if you have any questions.</p>
	<p>Clarification added for 0.9% physiological saline solution usage</p> <p>Please contact your local Roche Representative if you have any questions.</p>
Doc Rev. 3.0 10/2021	<p>Added cross reactivity wet laboratory testing to the analytical performance of SARS-CoV-2</p> <p>Added Clinical performance evaluation using prospective clinical samples, and clarified the specimens used for the clinical evaluation using retrospective samples.</p> <p>Please contact your local Roche Representative if you have any questions.</p>